Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) traded up 5.1% during trading on Tuesday . The stock traded as high as $15.56 and last traded at $15.42. 2,816,616 shares changed hands during trading, a decline of 78% from the average session volume of 12,575,572 shares. The stock had previously closed at $14.67.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on TEVA. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Finally, StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.
Check Out Our Latest Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Stock Up 9.0 %
The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock has a market cap of $18.13 billion, a price-to-earnings ratio of -10.98, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The firm's 50-day moving average is $18.70 and its 200 day moving average is $18.35.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.55% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the business. Oarsman Capital Inc. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $44,000. Smithfield Trust Co increased its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at $50,000. Finally, Venturi Wealth Management LLC bought a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at $60,000. Institutional investors and hedge funds own 54.05% of the company's stock.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
